A5027170167- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Hematological disorders and diagnostics
- Complement system in diseases
- Inflammatory Biomarkers in Disease Prognosis
- Kruppel-like factors research
- HIV/AIDS drug development and treatment
- Viral-associated cancers and disorders
- Iron Metabolism and Disorders
- Genetic factors in colorectal cancer
- Autoimmune and Inflammatory Disorders Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Venous Thromboembolism Diagnosis and Management
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- COVID-19 Clinical Research Studies
- Bone and Joint Diseases
- Adolescent and Pediatric Healthcare
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2014-2023
PURPOSE Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology America (HOLA) study was to describe patient characteristics treatment patterns American patients with MM, CLL, NHL. METHODS This a multicenter, retrospective, medical chart review NHL identified between January 1, 2006, December 31, 2015. Included were adults at least 1 year follow-up...
Thrombotic events are well documented in primary erythrocytosis, but it is uncertain if secondary etiologies increase the risk of thrombosis. This study aimed to determine causes erythrocytosis and identify its impact as a factor for thrombosis.Data were obtained from patients with between 2000 2017 at referral hospital Mexico City. Erythrocytosis was defined according 2016 WHO classification. Time thrombosis, major bleeding, or death compared among groups by etiology using Cox regression...
Objective To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America.Methods This chart review study (NCT02559583; 2008–2015)evaluated time to progression (TTP) overall survival (OS) among patients with CLL who initiate done (n = 261) two 96) lines of therapy (LOT) since diagnosis. Differences TTP OS were assessed by Kaplan-Meier analysis, a log-rank test for statistical significance. Association between therapeutic regimen risk disease or death...
Splenic myeloid metaplasia (SMM) is a kind of extramedullary hematopoiesis, whereas its clinical significance in wAIHA remains unclear. The aim this study evaluating the frequency and characteristics SMM, compared with splenic-congestion (SC).We included patients treated Mexican tertiary hospital between January 1992 December 2015. All received steroids as first-line treatment splenectomy second-line treatment.Among thirty-six splenectomized patients, 15 (41.6%) 21 (58.4%) were diagnosed SMM...
e18027 Background: Imatinib (IM) achieves complete cytogenetic response (CCyR) in 87% of chronic phase myeloid leukemia (CML-CP). Monitoring is fundamental, not achieving CCyR at 12m associated to higher rates progression. Karyotype (KT) standard for monitoring, FISH an alternative method, few studies have correlated both. In Latin America monitoring done 31% 3m and 54% 6m, 72% by KT 19% FISH. No study has validated its prognostic value countries were a high rate failure there no...
Topic: 32. Platelet disorders Background: Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially lethal entity characterized by microangiopathic anemia thrombocytopenia with severe ADAMTS13 deficiency, auto-antibodies being frequent in patients afflicted this disease. While low concentration considered the gold standard for diagnosis, clinical suspicion high PLASMIC score establishes tentative diagnosis justifies initiation of treatment. Mortality has decreased significantly...
e18566 Background: Chronic myelomonocytic leukemia (CMML) is the most aggressive of chronic leukemias, with a short overall survival and high transformation rate to acute leukemia. We investigated factors related blastic in Mexican population treated tertiary referral center Methods: Records patients diagnosed CMML between 2000-2015 were reviewed; incomplete data excluded. IBM SPSS Statics 21.0 software was used perform statistical analysis. Results: 54 included, median age 71 years an 16...
e19023 Background: Additional cytogenetic abnormalities (ACAs) that arise within Philadelphia-positive cells in patients with chronic myeloid leukemia (CML), have been reported 10%, 30%, and 90% of chronic, accelerated, blastic phase, respectively. Their presence is related to an increased risk treatment failure, leukemic progression, decreased survival. However, there no data the Latin American population. The aim this study, was outline impact ACAs emergence Mexican CML. Methods: We...
Background: Imatinib mesylate (IM) is the treatment of choice in patients with chronic myeloid leukemia (CML). Among its nonhematological adverse events, water retention most common, together weight gain. However, no thorough description body composition these has been informed. Therefore, our purpose was to evaluate nutritional status, and handgrip-strength CML treated IM. Methods: We conducted a cross-sectional study 78 (n = 48 men, 30 women) (82%) or accelerated (18%) phases. assessed...
ResumenEl 30